GLP-1 Hair Loss: Wegovy and Tirzepatide

Does Wegovy cause hair loss? What about tirzepatide?

Hair loss is reported in the US prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide). Both labels associate the reported events with weight reduction. Wegovy acts on the GLP-1 receptor; tirzepatide acts on both GIP and GLP-1 receptors. The Zepbound figures below come from its weight-management trials, so they should be described as Zepbound data rather than as one universal rate for every tirzepatide use.

We read the manufacturer’s current Wegovy label, revised June 2026, and cross-checked the relevant injection data against an FDA-hosted label. Zepbound figures come from the FDA-hosted prescribing information. The table describes the studied groups; it gives no instructions about choosing or changing a prescription.

The absolute differences are our subtraction of the label percentages; they are trial-period differences, not annual rates or individual forecasts. The label’s pooled Wegovy injection group and its separate higher-strength trial are different cohorts. The labels do not establish a head-to-head comparison between Wegovy and Zepbound. Current Wegovy label; FDA Wegovy cross-check; FDA Zepbound label.

GLP-1 hair loss in women: the figures that matter

Women reported hair loss more often than men in the label data. In the pooled Wegovy injection studies, 4% of women on the medicine reported hair loss versus 2% on placebo. In the separate higher-strength trial, the female figures were 8.4% in the higher-strength group, 5.4% in the standard-strength comparator and 1.5% on placebo. These are separate populations, so the two standard-strength female percentages should not be merged.

In Zepbound’s pooled trials, the figures were 7.1% of women on Zepbound versus 1.3% on placebo; for men they were 0.5% versus 0%. For women, 7.1 minus 1.3 equals 5.8 percentage points, or about 58 additional reports per 1,000 women over the trials. This is a report of hair-loss events, not a measurement of permanent follicle loss. Wegovy section 6.1; Zepbound section 6.1.

Why can shedding begin months after weight loss?

Telogen effluvium is an increase in shedding after a disruption to the hair cycle. The British Association of Dermatologists describes triggers including marked weight loss and extreme dieting. Shedding can appear around three months after a trigger and usually affects the scalp diffusely. That delay is why a timeline of weight change and eating patterns matters alongside the date you started a medicine. Read the dermatology leaflet.

This predates GLP-1 medicines. A 1976 JAMA report described nine people with heavy shedding after a weight-reduction programme and reported hair recovery within several months. It was a small case series about dieting, not a GLP-1 recovery study. Its value is the historical example of weight-loss-associated shedding; it cannot set your personal recovery deadline. Read the original abstract.

Will it stop after my weight stabilises?

If a clinician identifies a temporary shedding response and its trigger has resolved, improvement is a reasonable expectation. The British Association of Dermatologists describes a usual shedding phase of three to six months, followed by gradual recovery in volume. Ongoing triggers or another hair-loss condition can change that course. The AAD similarly explains that shedding can persist while a stressor continues. Telogen effluvium recovery; AAD shedding guidance.

These general timelines do not demonstrate that shedding always stops after a set number of months on Wegovy or tirzepatide. The label tables above record adverse events; they do not provide a hair-recovery curve. Arrange a review if shedding persists, especially beyond about six months, or if you notice a widening part or focal thinning.

How to stop hair loss from a GLP-1: useful steps for women and men

1. Speak with your prescriber. Describe the shedding and ask for an assessment before changing or stopping the medication.
2. Bring a timeline. Include medicine start dates, weight changes, reduced appetite, illness and the start of shedding. Photos can help describe changes in your part or overall density.
3. Review nutrition. If eating enough has become difficult, ask your clinician or a registered dietitian for an individual plan. A clinician can decide whether blood tests for iron deficiency, thyroid disease or another suspected cause are appropriate.
4. Use gentle hair care. Avoid repeated pulling and harsh handling while the cause is assessed.
5. Arrange a follow-up. Record whether shedding is easing and whether the part, crown or hairline continues to change.

The dermatology leaflet recommends a balanced diet and assessment for relevant underlying causes. Let that assessment guide supplements, rather than assuming every person who sheds needs the same product. Clinical assessment and self-care guidance.

What if this is also female pattern hair loss?

Telogen effluvium and androgenetic alopecia can appear together. Women’s pattern loss often shows as a widening central part and thinning over the top of the head. A clinician can distinguish diffuse shedding from pattern loss and consider whether both are contributing. Overlapping conditions; Female pattern description.

Read menopause and postpartum hair changes for other timing clues, how much hair loss is normal? for shedding context, and types of hair loss for the broader differential.

When should I get checked sooner?

Seek an assessment for sudden patches, scalp pain or inflammation, eyebrow loss, or continuing visible thinning. Contact your prescriber if you are struggling to eat adequately or your weight is changing faster than planned. Bring your observations rather than trying to decide the cause from a shower-drain count. The NHS recommends a GP assessment when hair loss worries you. NHS hair-loss guidance; AAD signs and symptoms.

When a laser cap enters the conversation

If a clinician identifies androgenetic (pattern) hair loss, discuss whether low-level laser therapy fits your situation. The manufacturer’s device-family clearance, FDA 510(k) K261253, is to promote hair growth in males with androgenic alopecia, Norwood-Hamilton IIa–V, or females with androgenic alopecia, Ludwig-Savin I–II, both with Fitzpatrick Skin Phototypes I–IV. Results vary.

Explore the Luxuel Laser Cap 272, or start with the hair-loss assessment to organise your questions. A clinician can assess the cause of your hair changes.

For a clinician-confirmed pattern diagnosis, read pattern hair loss explained and laser caps for women.

General educational information; ask a qualified clinician about your own hair loss. This content is not intended to diagnose, treat, cure, or prevent any disease. Results vary.